Triamcinolona Over is a depot injectable corticosteroid indicated for long-term treatment in cattle, sheep, horses, camels, pigs, dogs, and cats. It is indicated for use in non-infectious inflammatory processes of the joints and related tissues, symptomatic treatment of traumatic arthritis and tenosynovitis. Reduces pain and improves mobility within 24 hours of treatment activation. A single injection is usually enough to remove signs and injuries.
Triamcinolona is a preferred corticosteroid for joint treatment due to its chondroprotective effects and effective control of joint inflammation. While it remains detectable in joint fluid for as long as 15 days, it also is identifiable in the blood stream for four days, with cortisol suppression persisting for about 11 days. Previous studies have demonstrated that intramuscular injection of TA has anti-inflammatory effects on lung function for up to a month. While there might be some benefit to suppression of lung inflammation in horses with severe asthma, it is also possible that such treatment delays an accurate diagnosis and effective therapy. The glucocorticoid equine veterinarians have relied on for decades for fast pain relief.
Corticosteroids have been used in the treatment of laminitis; Parenteral is not recommended for that use. Cases of laminitis have been reported following the administration of Parenteral; the mechanism of that response has not been fully elucidated. Care is necessary when using any corticosteroid in the equine species.
Give this medication to your horse exactly as your veterinarian prescribes. If you miss giving your horse a dose of dexamethasone, give the next dose as soon as you remember or, if it is close to the next scheduled dose, return to the regular schedule. Do not double dose to catch up.
Every 1 ml, it contains:
Triamcinolone acetonide 6 mg
Formulation agents q.s.
Treatment of inflammation and allergic and dermatological disorders.
Animal species to which it is intended:
Cattle, sheep, horses, camels, pigs, dogs, and cats
DOSAGE AND ADMINISTRATION
0.04 ml per k.l.w., by subcutaneous or intramuscular route.